Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
不依赖冷链、无针粘膜病毒体疫苗,可预防粘膜水平的 HIV-1 感染
基本信息
- 批准号:10072724
- 负责人:
- 金额:$ 72.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY – OVERALL
This multi-PI application is a collaboration between Mymetics and the Texas Biomedical Research Institute
(TxBiomed), with Drs. Sylvain Fleury (Project 1 Lead; Mymetics) and Ruth Ruprecht (Project 2 Lead; TxBiomed)
serving as PIs. We seek to bring a promising HIV/AIDS vaccine approach to the clinic. The vaccine is based
upon influenza virosomes, enveloped virus-like particles that display on their surface elongated HIV gp41
peptides (virosome-P1) or recombinant truncated HIV gp41 (virosome-rgp41). Mymetics' Phase I clinical trial
with virosome-P1 in healthy women showed safety and immunogenicity. Two independent nonhuman primate
(NHP) studies demonstrated the safety and high efficacy of the combination of virosome-P1 + virosome rgp41
against repeated low-dose intravaginal challenges with a tier 2 R5 SHIV in Chinese and Indian-origin rhesus
macaques (RMs). In the latter, 78-87% efficacy was noted when the SHIV challenge dose was ~7x104 times the
median HIV inoculum in male-to-female HIV transmission. However, when this HIV inoculum was exceeded 105-
fold by an even higher SHIV inoculum, protection in Indian RMs was lost, implying a threshold effect whereby
vaccine-induced mucosal antibodies were unable to ward off the higher number of invading SHIV particles. The
soluble vaccine used in both NHP studies was unadjuvanted. To improve immunogenicity, Mymetics has
embedded the toll-like receptor (TLR)7/8 adjuvant 3M-052 into virosomal envelopes. Moreover, Mymetics has
developed a powdered form of virosomes that is no longer cold-chain dependent and can be administered as
intranasal (IN) spray, sublingual (SL) tablets, or packaged into oral capsules. We hypothesize that these novel
solid virosome formulations are significantly more immunogenic, particularly when administered via mucosal
routes, than the unadjuvanted liquid form used earlier in NHPs. The Specific Aims of this IPCAVD project are to:
1. Assess the immunogenicity of the new vaccine candidates, the newly 3M-052-adjuvanted HIV virosome-P1
and virosome-rgp41, under solid dosage forms delivered IN, SL, or orally to Indian RMs in order to select the
two most immunogenic formulations for subsequent mucosal prime/mucosal boost immunization.
2. Assess the efficacy of the cold-chain independent virosomal vaccine delivered by combined mucosal
immunization routes against repeated intrarectal challenges with the heterologous R5 clade B SHIVSF162P3.
Protected RMs will be rechallenged with an R5 tier 2 clade C SHIV.
3. Optimize the GMP manufacturing process for the selected virosomal formulations for mucosal delivery, and
4. Perform toxicology studies to show good safety profiles of the adjuvanted, solid-form vaccines given by
selected mucosal routes – and generate GMP vaccine for a Phase I trial to be conducted with the HVTN.
Our vaccine development plans represent major advances, as the novel needle-free, solid vaccine dosage forms
are cold-chain independent and will be mucosally delivered – unique aspects that make the novel virosomal
vaccines especially attractive for the developing world, where the AIDS epidemic remains a serious problem.
项目概要-总体
这个多PI应用程序是Mymetics和德克萨斯生物医学研究所之间的合作
Sylvain Fleury博士(项目1负责人; Mymetics)和Ruth Ruprecht博士(项目2负责人; TxBiomed)
作为PI。我们寻求将一种有希望的艾滋病毒/艾滋病疫苗方法引入临床。疫苗是基于
在流感病毒体上,在其表面展示的包膜病毒样颗粒延长了HIV gp 41
肽(病毒体-P1)或重组截短的HIV gp 41(病毒体-rgp 41)。Mymetics的I期临床试验
结果表明,病毒体P1在健康女性中的安全性和免疫原性均较好。两个独立的非人类灵长类动物
(NHP)研究证明了病毒体-P1+病毒体rgp 41的组合的安全性和高效性
在中国和印度恒河猴中对抗2级R5 SHIV的重复低剂量阴道内攻毒
猕猴(RM)。在后者中,当SHIV攻击剂量为约7 × 104倍于对照组时,观察到78-87%的疗效。
男性对女性艾滋病毒传播中的艾滋病毒接种中位数。然而,当这种艾滋病毒接种超过105-
倍,甚至更高的SHIV接种物,在印度RM的保护丢失,这意味着阈值效应,
疫苗诱导的粘膜抗体不能抵御更多数量的SHIV颗粒的入侵。的
在两个NHP研究中使用的可溶性疫苗是无佐剂的。为了提高免疫原性,Mymetics
将Toll样受体(TLR)7/8佐剂3 M-052包埋到病毒体包膜中。此外,Mymetics
开发了一种粉末状的病毒体,不再依赖于冷链,
鼻内(IN)喷雾剂、舌下(SL)片剂或包装成口服胶囊。我们假设这些小说
固体病毒体制剂的免疫原性显著更高,特别是当通过粘膜给药时,
途径,而不是在NHP早期使用的无佐剂液体形式。该IPCAVD项目的具体目标是:
1.评估新候选疫苗(新添加3 M-052佐剂的HIV病毒体-P1)的免疫原性
和病毒体-rgp 41,以IN、SL或口服递送给印度RM的固体剂型,
两种最具免疫原性的制剂用于随后的粘膜初免/粘膜加强免疫。
2.评估通过联合粘膜递送的非冷链依赖性病毒体疫苗的效力
针对用异源R5进化枝B SHIVSF 162 P3的重复直肠内攻击的免疫途径。
受保护的RM将使用R5 2级进化枝C SHIV进行再攻毒。
3.优化用于粘膜递送的选定病毒体制剂的GMP生产工艺,以及
4.进行毒理学研究,以显示通过以下方式给予的含佐剂固体疫苗的良好安全性
选择的粘膜途径-并产生GMP疫苗的I期试验将与HVTN进行。
我们的疫苗开发计划代表了重大进展,因为新型无针固体疫苗剂型
是冷链独立的,并将通过粘膜递送-独特的方面,使新的病毒体
疫苗对发展中国家特别有吸引力,因为艾滋病流行病仍然是一个严重的问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sylvain FLEURY其他文献
Sylvain FLEURY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sylvain FLEURY', 18)}}的其他基金
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
不依赖冷链、无针粘膜病毒体疫苗,可预防粘膜水平的 HIV-1 感染
- 批准号:
10401878 - 财政年份:2019
- 资助金额:
$ 72.72万 - 项目类别:
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
不依赖冷链、无针粘膜病毒体疫苗,可预防粘膜水平的 HIV-1 感染
- 批准号:
10624796 - 财政年份:2019
- 资助金额:
$ 72.72万 - 项目类别:
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
不依赖冷链、无针粘膜病毒体疫苗,可预防粘膜水平的 HIV-1 感染
- 批准号:
10158409 - 财政年份:2019
- 资助金额:
$ 72.72万 - 项目类别:
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
不依赖冷链、无针粘膜病毒体疫苗,可预防粘膜水平的 HIV-1 感染
- 批准号:
9919543 - 财政年份:2019
- 资助金额:
$ 72.72万 - 项目类别:
相似国自然基金
Supply Chain Collaboration in addressing Grand Challenges: Socio-Technical Perspective
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国青年学者研究基金项目
在大数据和复杂模型背景下探究更有效的Markov chain Monte Carlo算法
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
构建互穿网络结构中系带分子(tie chain)和缠结网络协同提升全聚合物太阳能电池力学与光伏性能
- 批准号:52003269
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于Service Chain的数据中心网络资源调度问题研究
- 批准号:61772235
- 批准年份:2017
- 资助金额:59.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: Chain Transform Fault: Understanding the dynamic behavior of a slow-slipping oceanic transform system
合作研究:链变换断层:了解慢滑海洋变换系统的动态行为
- 批准号:
2318855 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Continuing Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Standard Grant
言語の壁を超える低資源多言語Machine Speech Chain技術の構築
构建克服语言障碍的低资源多语言机器语音链技术
- 批准号:
23K21681 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A Data-Centric Mobile Edge Platform for Resilient Logistics & Supply Chain
以数据为中心的移动边缘平台,实现弹性物流
- 批准号:
LP220200893 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Linkage Projects
An Integrated Value Chain for the Coffee Industry
咖啡行业的综合价值链
- 批准号:
10078431 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Collaborative R&D
SUstainable EuroPean Rare Earth Elements production value chain from priMary Ores
来自原矿的可持续欧洲稀土元素生产价值链
- 批准号:
10091569 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
EU-Funded
EcoTraceAI: A Novel AI-based Platform for data collection and validation for measuring the environmental impacts of the supply chain in the fashion industry.
EcoTraceAI:一个基于人工智能的新型平台,用于数据收集和验证,用于衡量时尚行业供应链的环境影响。
- 批准号:
10114149 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
SME Support
An explainability oriented approach to manage dependent supply chain risks
一种以可解释性为导向的方法来管理相关供应链风险
- 批准号:
LP230100379 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Linkage Projects
Revolutionising the Defence Supply Chain through Space-enabled Materials & Manufacturing Processes (M&MP)
通过太空材料彻底改变国防供应链
- 批准号:
10087518 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Collaborative R&D
CAREER: Elucidating the Impact of Side-Chain Topology on the Structure-Property Relationship in Bottlebrush Polymers
职业:阐明侧链拓扑对洗瓶刷聚合物结构-性能关系的影响
- 批准号:
2340664 - 财政年份:2024
- 资助金额:
$ 72.72万 - 项目类别:
Continuing Grant














{{item.name}}会员




